First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Stud

By afschroeder • April 11, 2026

Gray JE, Neal JW, Patel JD, Liu SV, Veillon R, Reck M, Cappuzzo F, Cobo M, Reguart N, Fuentes Pradera J, Cho BC, Mok T, Mekan S, Safavi F, Fernando N, Chisamore M, Garon EB. First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study. Clin Cancer Res. 2026 Apr 10. doi: 10.1158/1078-0432.CCR-25-4485. Epub ahead of print. PMID: 41961582.

Tags: Hematology/Oncology, Publications

Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth

Shibata T, Bhat S, Cao D, Saito S, Khan N, Bernstein EA, Tokudome T, Okwan-Duodu D, Tourtellotte WG, Bernstein KE, Khan Z. Bioengineered iPSC-derived human[...]

Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape

Hennessy MA, Terman E, Idossa D, LeVee A, Leon-Ferre RA, McArthur H, Nanda R. Advanced Triple-Negative Breast Cancer: Emerging Therapies and a Changing Treatment Landscape.[...]

irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets

Bejan CA, Wang M, Venkateswaran S, Bergmann EA, Hiles L, Xu Y, Chandler GS, Brondfield S, Silverstein J, Wright F, de Dios K, Kim DM,[...]